Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elekta AB ( ($SE:EKTA.B) ) just unveiled an update.
Elekta will host a digital Strategic Update event on January 30, 2026, aimed at investors, analysts and other stakeholders, where President and CEO Jakob Just-Bomholt and the executive leadership team will outline the company’s strategic direction and latest innovations in precision radiation therapy. The event is positioned as a key platform for deepening engagement with the market, highlighting Elekta’s commitment to sustainable, outcome-focused cancer care and signaling future growth opportunities as it seeks to strengthen its role in global oncology treatment.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK52.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta AB is a Stockholm-headquartered medical technology company specializing in precision radiation therapy for cancer care. With a global workforce of about 4,500 employees and offices in more than 40 countries, Elekta focuses on developing sustainable, outcome-driven and cost-efficient oncology solutions, collaborating closely with healthcare providers to improve patient access to advanced cancer treatment. The company is listed on Nasdaq Stockholm.
YTD Price Performance: 5.73%
Average Trading Volume: 1,227,793
Technical Sentiment Signal: Hold
Current Market Cap: SEK22.92B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.